Skip to main content

Advertisement

Log in

Prevalence, incidence, and associated factors of avascular necrosis in Korean patients with systemic lupus erythematosus: a nationwide epidemiologic study

  • Original Article - Observational Research
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Avascular necrosis (AVN) is one of the most frequent types of organ damage in systemic lupus erythematosus (SLE). However, little is currently known about the epidemiology of AVN in SLE patients. The aim of this study was to estimate the prevalence and incidence of AVN in Korean patients with SLE based on National Health Insurance (NHI) claims data and to determine the risk factors for AVN among SLE patients. This study was conducted using the 2006–2010 data of 25,358 SLE patients from the NHI program. AVN cases were defined as those with at least one diagnosis of AVN. The prevalence was calculated by dividing the number of AVN cases by the number of SLE cases in the same year. The annual incidence was calculated by dividing the number of incident AVN cases by the number of SLE-prevalent cases not previously diagnosed with AVN. Patients who developed AVN in 2008–2010 were compared with SLE patients who did not develop AVN to identify any risk factors. The prevalence of AVN among SLE patients (2006–2010) was 31.5–34.2 per 1,000 persons and was similar in all the years studied. The incidence per 1,000 persons of AVN among SLE patients was 8.6 [95 % confidence interval (95 % CI) 6.9–10.3] in 2008, 9.8 (95 % CI 8.0–11.6) in 2009, and 8.4 (95 % CI 6.8–10.0) in 2010. Regression analysis indicated that taking an oral corticosteroid [odds ratio (OR) 2.12, 95 % CI 1.39–3.23] or an intravenous corticosteroid (OR 1.5, 95 % CI 1.2–1.89) was significantly associated with AVN. In addition, AVN was associated with use of immunosuppressive agents (OR 2.12, 95 % CI 1.66–2.72), hydroxychloroquine (OR 1.4, 95 % CI 1.09–1.81), and lipid-lowering agents (OR 1.78, 95 % CI 1.24–2.57) among the prescribed medications, and with hypertension (OR 1.39, 95 % CI 1.08–1.79) among the comorbidities. The prevalence and incidence of AVN among SLE patients, which were 31.5–34.2 and 8.4–9.8 per 1,000 persons, respectively, may be representative of the entire population of symptomatic AVN patients with SLE in Korea. AVN is associated with the use of corticosteroids, immunosuppressants, hydroxychloroquine, lipid-lowering agents, and with hypertension. Studies of large, prospective cohorts are needed to confirm these results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Mok MY, Farewell VT, Isenberg DA (2000) Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies? Ann Rheum Dis 59(6):462–467

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Uea-areewongsa P, Chaiamnuay S, Narongroeknawin P, Asavatanabodee P (2009) Factors associated with osteonecrosis in Thai lupus patients: a case control study. J Clin Rheumatol 15(7):345–349. doi:10.1097/RHU.0b013e3181ba3423

    Article  PubMed  Google Scholar 

  3. Sayarlioglu M, Yuzbasioglu N, Inanc M, Kamali S, Cefle A, Karaman O, Onat AM, Avan R, Cetin GY, Gul A, Ocal L, Aral O (2012) Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus. Rheumatol Int 32(1):177–182. doi:10.1007/s00296-010-1597-9

    Article  CAS  PubMed  Google Scholar 

  4. Fukushima W, Fujioka M, Kubo T, Tamakoshi A, Nagai M, Hirota Y (2010) Nationwide epidemiologic survey of idiopathic osteonecrosis of the femoral head. Clin Orthop Relat Res 468(10):2715–2724. doi:10.1007/s11999-010-1292-x

    Article  PubMed Central  PubMed  Google Scholar 

  5. Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME (2002) Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 32(2):94–124

    Article  PubMed  Google Scholar 

  6. Gladman DD, Urowitz MB, Chaudhry-Ahluwalia V, Hallet DC, Cook RJ (2001) Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Orheumatol 28(4):761–765

    CAS  Google Scholar 

  7. Kunyakham W, Foocharoen C, Mahakkanukrauh A, Suwannaroj S, Nanagara R (2012) Prevalence and risk factor for symptomatic avascular necrosis development in Thai systemic lupus erythematosus patients. Asian Paci J Allergy Immunol 30(2):152–157

    Google Scholar 

  8. Mok CC, Lau CS, Wong RW (1998) Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol 37(8):895–900

    Article  CAS  PubMed  Google Scholar 

  9. Mont MA, Glueck CJ, Pacheco IH, Wang P, Hungerford DS, Petri M (1997) Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol 24(4):654–662

    CAS  PubMed  Google Scholar 

  10. Migliaresi S, Picillo U, Ambrosone L, Di Palma G, Mallozzi M, Tesone ER, Tirri G (1994) Avascular osteonecrosis in patients with SLE: relation to corticosteroid therapy and anticardiolipin antibodies. Lupus 3(1):37–41

    Article  CAS  PubMed  Google Scholar 

  11. Cho SK, Sung YK, Choi CB, Bae SC (2012) Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data. Rheumatol Int 32(12):3851–3856. doi:10.1007/s00296-011-2312-1

    Article  CAS  PubMed  Google Scholar 

  12. Kim JY, Kim HJ, Jung SY, Kim KI, Song HJ, Lee JY, Seong JM, Park BJ (2012) Utilization of evidence-based treatment in elderly patients with chronic heart failure: using Korean Health Insurance claims database. BMC Cardiovasc Disord 12:60. doi:10.1186/1471-2261-12-60

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Sung YK, Cho SK, Choi CB, Bae SC (2013) Prevalence and incidence of rheumatoid arthritis in South Korea. Rheumatol Int 33(6):1525–1532. doi:10.1007/s00296-012-2590-2

    Article  PubMed  Google Scholar 

  14. Shim JS, Sung YK, Joo YB, Lee HS, Bae SC (2013) Prevalence and incidence of systemic lupus erythematosus in South Korea. Rheumatol Int. doi:10.1007/s00296-013-2915-9

    PubMed  Google Scholar 

  15. Kang JS, Park S, Song JH, Jung YY, Cho MR, Rhyu KH (2009) Prevalence of osteonecrosis of the femoral head: a nationwide epidemiologic analysis in Korea. J Arthroplasty 24(8):1178–1183. doi:10.1016/j.arth.2009.05.022

    Article  PubMed  Google Scholar 

  16. Yamaguchi R, Yamamoto T, Motomura G, Ikemura S, Iwamoto Y (2011) Incidence of nontraumatic osteonecrosis of the femoral head in the Japanese population. Arthritis Rheum 63(10):3169–3173. doi:10.1002/art.30484

    Article  PubMed  Google Scholar 

  17. Nakamura J, Saisu T, Yamashita K, Suzuki C, Kamegaya M, Takahashi K (2010) Age at time of corticosteroid administration is a risk factor for osteonecrosis in pediatric patients with systemic lupus erythematosus: a prospective magnetic resonance imaging study. Arthritis Rheum 62(2):609–615. doi:10.1002/art.27236

    PubMed  Google Scholar 

  18. Asherson RA, Liote F, Page B, Meyer O, Buchanan N, Khamashta MA, Jungers P, Hughes GR (1993) Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol 20(2):284–288

    CAS  PubMed  Google Scholar 

  19. Oinuma K, Harada Y, Nawata Y, Takabayashi K, Abe I, Kamikawa K, Moriya H (2001) Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis 60(12):1145–1148

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Sung YK, Hur NW, Sinskey JL, Park D, Bae SC (2007) Assessment of damage in Korean patients with systemic lupus erythematosus. J Rheumatol 34(5):987–991

    PubMed  Google Scholar 

  21. Fialho SC, Bonfa E, Vitule LF, D’Amico E, Caparbo V, Gualandro S, Pereira RM (2007) Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus. Lupus 16(4):239–244. doi:10.1177/0961203307076771

    Article  CAS  PubMed  Google Scholar 

  22. Nagasawa K, Ishii Y, Mayumi T, Tada Y, Ueda A, Yamauchi Y, Kusaba T, Niho Y (1989) Avascular necrosis of bone in systemic lupus erythematosus: possible role of haemostatic abnormalities. Ann Rheum Dis 48(8):672–676

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Calvo-Alen J, McGwin G, Toloza S, Fernandez M, Roseman JM, Bastian HM, Cepeda EJ, Gonzalez EB, Baethge BA, Fessler BJ, Vila LM, Reveille JD, Alarcon GS (2006) Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case–control study. Ann Rheum Dis 65(6):785–790. doi:10.1136/ard.2005.040428

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Nagasawa K, Tada Y, Koarada S, Horiuchi T, Tsukamoto H, Murai K, Ueda A, Yoshizawa S, Ohta A (2005) Very early development of steroid-associated osteonecrosis of femoral head in systemic lupus erythematosus: prospective study by MRI. Lupus 14(5):385–390

    Article  CAS  PubMed  Google Scholar 

  25. Aranow C, Zelicof S, Leslie D, Solomon S, Barland P, Norman A, Klein R, Weinstein A (1997) Clinically occult avascular necrosis of the hip in systemic lupus erythematosus. J Rheumatol 24(12):2318–2322

    CAS  PubMed  Google Scholar 

  26. Kim HA, Song YW (1996) Avascular Necrosis in a corticosteroid-treated rheumatic disease population. J Korean Rheum Assoc 3:110–117

    Google Scholar 

  27. Prasad R, Ibanez D, Gladman D, Urowitz M (2007) The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: a nested case–control study of inception patients. Lupus 16(3):157–162

    CAS  PubMed  Google Scholar 

  28. Ferrari P, Schroeder V, Anderson S, Kocovic L, Vogt B, Schiesser D, Marti HP, Ganz R, Frey FJ, Kohler HP (2002) Association of plasminogen activator inhibitor-1 genotype with avascular osteonecrosis in steroid-treated renal allograft recipients. Transplantation 74(8):1147–1152. doi:10.1097/01.tp.0000035848.73883.1b

    Article  CAS  PubMed  Google Scholar 

  29. Yang P, Liu YF, Yang L, Wei Q, Zeng H (2010) Mechanism and clinical significance of the prothrombotic state in patients with essential hypertension. Clin Cardiol 33(6):E81–E86. doi:10.1002/clc.20719

    Article  PubMed  Google Scholar 

  30. Caramaschi P, Biasi D, Dal Forno I, Adami S (2012) Osteonecrosis in systemic lupus erythematosus: an early, frequent, and not always symptomatic complication. Autoimmune Dis 2012:725249. doi:10.1155/2012/725249

    PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported in part by grants from the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (Nos. A080588 and A102065).

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sang-Cheol Bae.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 17 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Joo, Y.B., Sung, YK., Shim, JS. et al. Prevalence, incidence, and associated factors of avascular necrosis in Korean patients with systemic lupus erythematosus: a nationwide epidemiologic study. Rheumatol Int 35, 879–886 (2015). https://doi.org/10.1007/s00296-014-3147-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-014-3147-3

Keywords

Navigation